Depletion of tristetraprolin in breast cancer cells increases interleukin-16 expression and promotes tumor infiltration with monocytes/macrophages

Carcinogenesis

Volumn 34, Issue 4, 2013, Pages 850-857

  Milke, Larissa ^a   Schulz, Kathrin ^a   Weigert, Andreas ^a   Sha, Weixiao ^a   Schmid, Tobias ^a   Brüne, Bernhard ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 16; MESSENGER RNA; TRISTETRAPROLIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL INFILTRATION; CELL INTERACTION; CONTROLLED STUDY; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SUPERNATANT; TUMOR MICROENVIRONMENT; TUMOR SPHEROID; TUMOR XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHEMOTAXIS, LEUKOCYTE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; INTERLEUKIN-16; MACROPHAGES; MICE; MICE, NUDE; MONOCYTES; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PROGNOSIS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; SPHEROIDS, CELLULAR; TRANSPLANTATION, HETEROLOGOUS; TRISTETRAPROLIN; TUMOR MICROENVIRONMENT; UP-REGULATION;

EID: 84875959686     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs387     Document Type: Article

References (50)

1. Carballo,E. et al. (1998) Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science, 281, 1001-1005.
2. Carballo,E. et al. (2000) Evidence that tristetraprolin is a physiological regulator of granulocyte-macrophage colony-stimulating factor messenger RNA deadenylation and stability. Blood, 95, 1891-1899.
3. Hoppstädter,J. et al. (2012) Glucocorticoid-induced leucine zipper is downregulated in human alveolar macrophages upon Toll-like receptor activation. Eur. J. Immunol., 42, 1282-1293.
4. Lai,W.S. et al. (2000) Interactions of CCCH zinc finger proteins with mRNA. Binding of tristetraprolin-related zinc finger proteins to Au-rich elements and destabilization of mRNA. J. Biol. Chem., 275, 17827-17837.
5. Werno,C. et al. (2010) A combination of hypoxia and lipopolysaccharide activates tristetraprolin to destabilize proinflammatory mRNAs such as tumor necrosis factor-alpha. Am. J. Pathol., 177, 1104-1112.
6. Zhao,W. et al. (2011) Tristetraprolin regulates interleukin-6 expression through p38 MAPK-dependent affinity changes with mRNA 3' untranslated region. J. Interferon Cytokine Res., 31, 629-637.
7. Bourcier,C. et al. (2011) Constitutive ERK activity induces downregulation of tristetraprolin, a major protein controlling interleukin8/CXCL8 mRNA stability in melanoma cells. Am. J. Physiol., Cell Physiol., 301, C609-C618.
8. Lee,H.H. et al. (2010) Tristetraprolin regulates expression of VEGF and tumorigenesis in human colon cancer. Int. J. Cancer, 126, 1817-1827.
9. Marderosian,M. et al. (2006) Tristetraprolin regulates Cyclin D1 and c-Myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling. Oncogene, 25, 6277-6290.
10. Al-Souhibani,N. et al. (2010) The RNA-binding zinc-finger protein tristetraprolin regulates AU-rich mRNAs involved in breast cancer-related processes. Oncogene, 29, 4205-4215.
11. Carrick,D.M. et al. (2007) Comparative expression of tristetraprolin (TTP) family member transcripts in normal human tissues and cancer cell lines. Arch. Biochem. Biophys., 462, 278-285.
12. Gebeshuber,C.A. et al. (2009) miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep., 10, 400-405.
13. Young,L.E. et al. (2009) The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis. Gastroenterology, 136, 1669-1679.
14. Brennan,S.E. et al. (2009) The mRNA-destabilizing protein tristetraprolin is suppressed in many cancers, altering tumorigenic phenotypes and patient prognosis. Cancer Res., 69, 5168-5176.
15. Allavena,P. et al. (2008) The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit. Rev. Oncol. Hematol., 66, 1-9.
16. Mantovani,A. et al. (2006) Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev., 25, 315-322.
17. Bingle,L. et al. (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol., 196, 254-265.
18. Leek,R.D. et al. (1996) Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res., 56, 4625-4629.
19. Porta,C. et al. (2007) Tumor promotion by tumor-associated macrophages. Adv. Exp. Med. Biol., 604, 67-86.
20. Lin,E.Y. et al. (2006) Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res., 66, 11238-11246.
21. Lewis,C.E. et al. (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res., 66, 605-612.
22. Mantovani,A. et al. (2010) The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev., 21, 27-39.
23. Chupp,G.L. et al. (1998) Tissue and T cell distribution of precursor and mature IL-16. J. Immunol., 161, 3114-3119.
24. Cruikshank,W.W. et al. (2000) Interleukin-16. J. Leukoc. Biol., 67, 757-766.
25. Arima,M. et al. (1999) Expression of interleukin-16 by human epithelial cells. Inhibition by dexamethasone. Am. J. Respir. Cell Mol. Biol., 21, 684-692.
26. Bellini,A. et al. (1993) Bronchial epithelial cells of patients with asthma release chemoattractant factors for T lymphocytes. J. Allergy Clin. Immunol., 92, 412-424.
27. Laberge,S. et al. (1997) Expression of IL-16 in allergen-induced late-phase nasal responses and relation to topical glucocorticosteroid treatment. J. Allergy Clin. Immunol., 100, 569-574.
28. Gao,L.B. et al. (2009) The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer. Carcinogenesis, 30, 295-299.
29. Alexandrakis,M.G. et al. (2004) Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity. Am. J. Hematol., 75, 101-106.
30. Koike,M. et al. (2002) Relationship between CD4(+)/CD8(+) T cell ratio and T cell activation in multiple myeloma: reference to IL-16. Leuk. Res., 26, 705-711.
31. Griseri,P. et al. (2011) A synonymous polymorphism of the Tristetraprolin (TTP) gene, an AU-rich mRNA-binding protein, affects translation efficiency and response to Herceptin treatment in breast cancer patients. Hum. Mol. Genet., 20, 4556-4568.
32. Stoecklin,G. et al. (2003) A novel mechanism of tumor suppression by destabilizing AU-rich growth factor mRNA. Oncogene, 22, 3554-3561.
33. Johnson,B.A. et al. (2002) Multiple tristetraprolin sequence domains required to induce apoptosis and modulate responses to TNFalpha through distinct pathways. Oncogene, 21, 4237-4246.
34. Mantovani,A. et al. (2011) Cancer-promoting tumor-associated macrophages: new vistas and open questions. Eur. J. Immunol., 41, 2522-2525.
35. Wong,K.L. et al. (2012) The three human monocyte subsets: implications for health and disease. Immunol. Res., 53, 41-57.
36. Ziegler-Heitbrock,L. (2007) The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J. Leukoc. Biol., 81, 584-592.
37. Chen,Y.L. et al. (2006) Differential regulation of ARE-mediated TNFalpha and IL-1beta mRNA stability by lipopolysaccharide in RAW264.7 cells. Biochem. Biophys. Res. Commun., 346, 160-168.
38. Ogilvie,R.L. et al. (2009) Tristetraprolin mediates interferon-gamma mRNA decay. J. Biol. Chem., 284, 11216-11223.
39. Stoecklin,G. et al. (2000) Somatic mRNA turnover mutants implicate tristetraprolin in the interleukin-3 mRNA degradation pathway. Mol. Cell. Biol., 20, 3753-3763.
40. Suswam,E. et al. (2008) Tristetraprolin down-regulates interleukin-8 and vascular endothelial growth factor in malignant glioma cells. Cancer Res., 68, 674-682.
41. Anborgh,P.H. et al. (2010) Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J. Cell. Mol. Med., 14, 2037-2044.
42. Dave,H. et al. (2011) Transforming growth factor beta 2: a predictive marker for breast cancer. Indian J. Exp. Biol., 49, 879-887.
43. Dufour,J.H. et al. (2002) IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J. Immunol., 168, 3195-3204.
44. Shevde,L.A. et al. (2010) Osteopontin: an effector and an effect of tumor metastasis. Curr. Mol. Med., 10, 71-81.
45. Martinez,F.O. (2009) The transcriptome of human monocyte subsets begins to emerge. J. Biol., 8, 99.
46. Zhao,C. et al. (2009) Identification of novel functional differences in monocyte subsets using proteomic and transcriptomic methods. J. Proteome Res., 8, 4028-4038.
47. Gordon,S. et al. (2005) Monocyte and macrophage heterogeneity. Nat. Rev. Immunol., 5, 953-964.
48. Kovacs,E. (2001) The serum levels of IL-12 and IL-16 in cancer patients. Relation to the tumour stage and previous therapy. Biomed. Pharmacother., 55, 111-116.
49. Zhu,J. et al. (2010) IL-16 polymorphism and risk of renal cell carcinoma: association in a Chinese population. Int. J. Urol., 17, 700-707.
50. Mathy,N.L. et al. (2000) Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. Immunology, 100, 63-69.